MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 11.02.2026
Bristol-Myers Squibb Company Langfristiger Schuldenstrom 2011-2026 | BMY
Langfristiger Schuldenstrom Jährlich Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 202 M | 181 M | 162 M | 136 M | 169 M | 2 B | 133 M | 1.25 B | - | 749 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2 B | 133 M | 553 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
3.58 M | $ 8.74 | 0.23 % | $ 86.4 M |  USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.62 | -1.09 % | $ 8.71 B |  Australia |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
45 M | $ 98.41 | 1.77 % | $ 27.2 B | Germany |
 |
Cabaletta Bio
CABA
|
3.46 M | $ 3.26 | 1.87 % | $ 328 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 21.38 | 0.09 % | $ 999 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
364 K | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.56 | 6.12 % | $ 401 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.05 | 4.45 % | $ 5.02 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 4.15 | -0.95 % | $ 444 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 25.09 | 4.02 % | $ 3.19 B | USA |
 |
Chimerix
CMRX
|
642 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
1.16 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.55 M | $ 33.33 | 2.27 % | $ 2.21 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.48 | 0.68 % | $ 394 M |  Britain |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | USA |
 |
Evogene Ltd.
EVGN
|
716 K | $ 0.82 | 0.02 % | $ 27.9 M | Israel |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
|
Forte Biosciences
FBRX
|
416 K | $ 32.42 | 5.95 % | $ 420 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | Britain |
 |
CTI BioPharma Corp.
CTIC
|
781 K | - | - | $ 1.2 B | USA |